In this article
/ Download pdf version of this article
Inflammatory bowel disease – the role of faecal calprotectin
|Tests for inflammatory bowel disease
||not widely available
|pANCA, ASCA, Anti-CBir1, Anti-Omp C, Anti-l-2
Clinical assessment of intestinal inflammation can be problematic. Clinicians often under or over-estimate the degree
of inflammation present due to the subjective nature of many gastrointestinal symptoms.
When inflammatory bowel disease (IBD) is suspected clinically, laboratory testing can help rule out other causes of
diarrhoea and abdominal pain. However, a definitive diagnosis of IBD is made histologically by bowel biopsy.
- Reasonably new biomarker, unfunded (NZ$90 per assay)1
- Usually a specialist request
- Can be useful in differentiating between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), in symptomatic
patients with only slightly raised CRP
- Does not help determine the cause of inflammation1
- A single faecal calprotectin of <60 μg/g is a good negative predictor for inflammatory change2
This test is currently not widely available. Most gastroenterologists will proceed directly to colonoscopy and biopsy
if there are suggestive symptoms.
Antibody tests are sometimes requested by specialists to help differentiate between ulcerative colitis and Crohn’s
disease. None of the antibody tests are specific or sensitive enough to be used to diagnose either condition but may provide
some additional information. The current view is that they have little role in primary care.3
- Gearry R, Barclay M, Florkowski C et al. Faecal calprotectin: the case for a novel non-invasive way of
assessing intestinal inflammation. NZMJ May 2005.Vol 118;1214.
- Dolwani S, Metzner M, Wassell J et al. Diagnostic accuracy of faecal calprotectin estimation in prediction
of abnormal small bowel radiology. Aliment Pharmacol Ther 2004 Sep; 20(6):615-21.
- Personal communication Assoc. Professor Alan Fraser, Mercy Specialist Centre, Auckland.